A novel platform using adenovirus 5 vectors with three TAAs targeted, including prostate-specific antigen (PSA), brachyury, and MUC-1, has been developed for a cancer vaccine and is well tolerated in the phase I study of metastatic castration-resistant prostate cancer [91]. The gene discussed is KLK3; the disease is prostate cancer.